In The News

Scrip Quotes Eric Wu on HFCAA Compliance Considerations for Chinese Biotech Companies

Practices: Asia Pacific, China Life Sciences, Capital Markets Industries: Healthcare & Life Sciences

“The dark clouds of potential US stock delisting looming large” for several major Chinese biotech companies, Scrip recently reported. The April 26 piece, titled “BeiGene, Zai Lab Look To Clear US Delisting Uncertainties,” reviews actions being taken to satisfy disclosure and transparency regulations enacted under the Holding Foreign Companies Accountable Act (HFCAA). Insights from life sciences partner Eric Wu (Shanghai) are included in the article.

Cookie Settings